Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction

Next Previous
Trial Profile

A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms ALTIC

    • Most Recent Events

    • 02 Nov 2017 Primary endpoint (platelet reactivity measured in P2Y12 reaction units (PRU) at the end of the 2 study periods (pre-crossover and post-crossover) has been met, as per results presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
    • 02 Nov 2017 Results comparing low dose ticagrelor platelet reactivity to standard dose of clopidogrel, presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
    • 13 Jul 2017 Status changed from recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top